相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Iowa HHS awarded funding to the Iowa Poison Control Center to launch I-BEACON, a program expanding access to life-saving opioid treatment across the state. - The initiative provides healthcare providers with 24/7 clinical consultation and evidence-based guidance on buprenorphine initiation and management for opioid use disorder. - The program is funded through Iowa's opioid settlement, which is sending $186 million to the state from pharmacy chains and drug manufacturers. - The CDC estimates 17,000 Iowans are addicted to opioids, with 172 opioid-related deaths reported in 2024.
- Clinical trials offer patients with metastatic bladder cancer access to promising therapies while advancing cancer research, with today's standard treatments having once been clinical trials themselves. - Experts emphasize that patients should discuss clinical trial options early with their oncologists, as trials are increasingly available across first-line, maintenance, and post-progression settings. - Biomarkers such as FGFR2, FGFR3 alterations and HER2 overexpression have become increasingly important in bladder cancer clinical trials, guiding eligibility for targeted therapies. - Multiple registries including ClinicalTrials.gov, the National Cancer Institute, and the Bladder Cancer Advocacy Network provide searchable databases to help patients identify actively enrolling studies.
- Iowa continues to face some of the highest cancer rates in the nation, underscoring the urgent need for accessible radiation oncology services. - UnityPoint Health – Trinity Cancer Center and University of Iowa Health Care now offer advanced radiation therapy locally in the Quad Cities, reducing travel burdens for patients requiring frequent treatments. - Modern radiation oncology has advanced with improvements in imaging, treatment planning, and delivery systems that allow better tumor targeting while minimizing side effects. - Up to 40 percent of cancer cases are preventable through lifestyle choices, and routine screenings can identify pre-cancers before they spread, significantly improving survival rates.
- A large real-world clinical trial involving 384 fibromyalgia patients across 28 clinics found that adding TENS to physical therapy significantly reduced movement-evoked pain by 1.2 points on a 10-point scale compared to physical therapy alone. - The study demonstrated that TENS therapy specifically targets both movement-associated pain and fatigue, with 72% of patients reporting improvement compared to 51% receiving physical therapy only. - Unlike traditional pain medications that lose effectiveness over time, TENS maintained its therapeutic benefits for at least six months, with 81% of participants finding it helpful and 55% using it daily at the study's end. - The treatment showed a dose-dependent response with no serious adverse events, positioning TENS as a safe, accessible, and cost-effective addition to fibromyalgia management protocols.
- Harness Therapeutics has nominated HRN001, a first-in-class antisense oligonucleotide targeting FAN1 nuclease, as its lead drug candidate for Huntington's disease treatment. - The company established a clinical advisory board comprising seven leading Huntington's disease experts to guide HRN001's progression toward first-in-human studies planned for 2027. - HRN001 leverages Harness' proprietary MISBA® platform to precisely upregulate FAN1 protein levels, addressing somatic expansion which drives Huntington's disease progression. - Preclinical studies demonstrate that HRN001 achieves robust FAN1 upregulation and slows somatic expansion in Huntington's disease models while showing favorable pharmacokinetic and tolerability profiles.
